{"title": "A", "body": "Breastfeeding, 1 assessment score for, 263, 263t attitudes toward, 30, 210, 632, 633t barriers to, 1-3 benefits for infant, 215-219, 219t, 220b benefits for mother, 218t-219t, 219-223, 220b cessation rate for, 263, 263t commercial discharge packs and, 25-30, 29f contraindications to, 1, 223-227, 224t, 226t, 964, 1010 definitions of, 18-19, 25f, 155-156, 155b, 201-202 demographic factors for, 15-18, 22t disadvantages of, 227-228 duration of, 18-25, 23f-25f, 26t-28t employment and, 630-631, 631f recommendations for, 322t ethnic factors for, 12-15, 14f, 14t-21t, 18f failure at, 203-204, 210-212 frequency of, 11-12 history of, 4-30, 8f-9f, 12t-13t issues for, 1-4 model policy for, 1007-1010, 1009t morbidity and mortality studies of, 29t, 30-34, 31t, 32f-34f, 35t-36t national goals for, 2, 2t, 3f papal support for, 36 positions for, 8, 8f, 247-248, 475, 475f-476f prolonged, 114, 337, 341, 349-355 promotion of, 1, 196 federal activities for, 4, 7f key elements for, 6b-7b national campaign for, 36-37, 37f in prenatal setting, 1074-1076 reasons for, 240 rejection of, 209-212, 333 sources of advice on, 30t ten steps to successful, 7b, 1007, 1009t unrestricted, 18-19, 202-203 Breastfeeding management (Continued) let-down reflex in, 258-263, 259f-260f, 261t, 262f nipple problems in, 253-256, 253f, 255f , 256b nursing at delivery in, 244-245, 246f, 247b for near-term infant, 539, 1020-1024, 1024t office practice of, 278 peripartum, 233 ABM protocol for, 998-1000 cesarean delivery and, 239 labor drugs and anesthesia in, 238-239 sucking stimulus and prolactin in, 239 suckling in, 233-239, 234b-235b, 236f postnatal, 263-278, 263t breast and nipple problems in, 266-277, 267f-268f, 270f abscesses of, 413, 559-560, 559f, 593, 910t-924t, 995 apoptosis in, 62-63, 93-94 asymmetrical, 596-597, 597f dermatitis of, 599-600 engorgement of. See Engorgement. fat necrosis of, 594 fibrocystic disease of, 593 galactography of, 566f, 593 Breasts (Continued) gross anatomy of, 40-55 abnormalities in, 44-46, 44f-45f, 45b anatomic location in, 43-44, 43f-44f blood supply in, 50-52, 53f corpus mammae in, 45f, 46, 47f developmental stage and, 40, 41t, 43f, 63, 63t embryonic development in, 40, 41t, 64-65, 65f fetal and prepubertal development in, 41-42, 42f innervation in, 53-55, 54f lymphatic drainage in, 52-53, 53f nipple and areola in, 46-50, 48f-52f pubertal development in, 42f, 43, 44t growth of, 65-76 menstrual cycle and, 66 pregnancy and, 66-68, 67f-69f prepubertal, 65-66 pubertal, 66 hematomas of, 594 hemodynamic changes in, 78-85, 79f hormone production by, 83 hypertrophy of, 594-596, 594f-596f inflammation of. See Mastitis. intermediary metabolism of, 88, 88f lumps and cysts in, 220-221, 592-594 microscopic anatomy of, 48f, 55-60, 56t, 57f lactation and, 58-59, 59f mature mammary gland in, 48f, 57-58 postlactation regression and, 59-60 pregnancy and, 58, 58f neonatal, 489 painful, 266, 269-277, 954t-955t, 1089 postlactation involution of, 82, 93-94, 598, 598f prenatal examination of, 240, 240f-241f preparation of, 242, 647-648, 653- 133-134 CPT codes, 742, 744-745, 745t Cradle position, 247 C-reactive protein, 555 Creamatocrit, 523, 703-704, 1087 Creamatocrit Plus, 703-704 Creatine, 740t-741t Creatinine, 103t Crohn disease, 35t, 480-482, 583 Cromolyn, 752t-891t Cross-cradle hold, 247 Cross-nursing, 661-662, 1087 , 239, 245-246, 375-376, 550-551, 1051 mother-infant interaction at, 197-199, 198f nursing at, 244-245, 246f, 247b, 999-1000 155-156, 155b Dothiepin, 752t-891t, 394 Doulas, 11, 207, 241, 1088 Down syndrome, 487-488, 1049 -1050 Doxapram, 752t-891t Doxazosin, 752t-891t Doxepin, 752t-891t Doxorubicin, 752t-891t Doxycycline, 752t-891t, 457 Drip milk, 515, 695 Droplet precautions, 408 Drug abuse, 224t, 227, 380-381, 1082 , 106t, [109] [110] [111] [112] [113] [114] [115] [116] [117] 110t, [120] [121] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] 120 nonprotein nitrogen in, 120t, 121, 122t nucleotides in, [121] [122] [123] 123t, 178t oligosaccharides and glycoconjugates in, [124] [125] 126t, [133] [134] 121 prostaglandins in, [145] [146] 145f proteins in, [117] [118] [119] 117t, 118f, 120t vitamins in, [134] [135] [136] [137] 134t, [108] [109] 180 Measles, [437] [438] 439t, Oligosaccharides in milk, 305t-306t bioactivity of, 171-173, 172t, 181-182 colostrum, 103 mature, 124-125 Olopatadine, 752t-891t Olsalazine, 752t-891t Omega-3 fatty acids, 115, 287-289, 523, 1071 Omeprazole, 752t-891t, 378 Ondansetron, 752t-891t One-vs. two-breast feedings, 265-266, 344-345, 350- , 34-36, 202-203, 203t, 275, 965 Paget disease, 592 Pain breast, 266, 269-277, 956f, 1089 nipple, 253-254, 256b, 269-277, 600, 956f Palate abnormal, 499 cleft, 500-508, 501f, 501t, 1061 -1063 , 752t-891t, 376 Pennyroyal, 388t-389t Pentamidine, 752t-891t Pentazocine, 752t-891t, 1050 -1051 , 1053 Pentobarbital, 752t-891t Pentoxifylline, 752t-891t Peppermint, 383, 600 Peptide histidine methionine, 144t Peptides, hormonally active, 143-144, 144t Peptide YY, 144t Perinatal, definition of, 1089 Perindopril, 752t-891t Perioral stimulation, 476 Permethrin, 752t-891t Perphenazine, 752t-891t Personality infant, 206-207 maternal, 203-204 Pertussis, 415, 910t-924t Pesticides, 395-397 Peyer patches, 158f, 180 pH drug ionization and, 366-367 gastric, 162 milk, 92f, 103t, 126t, 133-134, 134t Phagocytes, defects in, 156b Phantom let-down, 263 Pharmacokinetics, 365-369, 366f, 367t Pharmacologic food reaction, 622 Phenacetin, 752t-891t Phencyclidine (PCP), 752t-891t, 1083 "}